Pharma Catalysts
Scope
Catalyst

Mon, Jun 22, 2026

1 updates
MRK
6:45 AM

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in moderately to severely active UC in a Phase 3 trial Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in inflammatory bowel disease (IBD) and other immune-mediated inflammatory conditions RAHWAY,...

Trial Results • Phase 3Results event Wed, Dec 31, 2025merck.com

Mon, Jun 8, 2026

2 updates
MRK
4:39 PM

Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Multiple Mechanisms of Action, including Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle – – Islatravir/Lenacapavir has the Potential to be the First Approved...

Trial Results • Phase 3Topline results Mon, Jun 8, 2026, 4:39 PM EDTmerck.com
MRK
4:30 PM

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

RAHWAY, N.J. & FOSTER CITY, Calif.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy ® (sacituzumab govitecan-hziy) in combination with KEYTRUDA ® (pembrolizumab),...

Trial Results • Phase 3Results event Wed, Dec 31, 2025merck.com

Mon, May 18, 2026

1 updates
MRK
6:45 AM

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

Sac-TMT is the first TROP2 ADC to improve OS and PFS compared to chemotherapy in patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and anti-PD-1/L1 immunotherapy in a global Phase 3 study RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE:...

Trial Results • Phase 3Results event Wed, Dec 31, 2025merck.com